DSSG Group: Breast

Oligometastatic Breast Cancer (OMBC)

To determine if the addition of SABR treatment towards the oligometastatic sites in addition to the standard first-line treatment of care can improve progression-free survival (PFS) for patients.

human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor [HR]-negative and HR-positive) unresectable and/or metastatic breast cancer.

The primary endpoint of interest in this study is time to next treatment (TTNT), a measure that will determine how long T-DXd allows patients to derive clinical benefit from the study drug.

Triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery

to compare the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician’s choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery

Breast cancer patients over 16 years old, male or female with central nervous disease.

PRIMROSE Cerebrospinal Fluid (CSF) Study aims to collect and investigate CSF samples and related data from patients with central nervous system disease secondary to breast cancer.

High-risk early triple negative breast cancer (TNBC) without mutations in the BRCA1 or BRCA2 gene. For this study high-risk early TNBC is defined as any presence of TNBC that still remains in the breast or lymph node tissue after receiving treatment and undergoing surgery.

The purpose of this study is to see if sacituzumab govitecan in combination with pembrolizumab can improve outcomes and delay the return of disease in patients with high-risk early TNBC when compared to pembrolizumab alone or pembrolizumab in combination with capecitabine.

ER+/HER2- early breast cancer with intermediate-high or high risk of recurrence

The purpose of this study is to measure the safety and demonstrate the superiority of camizestrant +/- abemaciclib as compared to standard endocrine therapy +/- abemaciclib by assessment of invasive breast cancer-free survival

Premenopausal patients with ER-positive/HER2-negative early breast cancer

A Window-of-Opportunity trial of giredestrant +/- triptorelin vs. anastrozole + triptorelin in premenopausal patients with ER-positive/HER2-negative early breast cancer.

ER+/HER2- early-stage breast cancer with ctDNA relapse.

To evaluate whether elacestrant can delay occurrence of distant metastasis or death when compared to standard endocrine therapy in ER+/HER2- patients with ctDNA relapse.

No new patients will be recruited to this study. The original study involved patients with breast cancer treated with Trastuzumab.If you participated in the CTRIAL-IE (ICORG) 08-01 CADY study on cardiac dysfunction in HER-2 positive breast cancer patients, please read this important data protection notice. Cancer Trials Ireland, in collaboration with Abbott Laboratories, is conducting a follow-up sub-study to re-test stored biological samples using advanced biomarker technology and review medical records for cardiovascular outcomes. This research aims to improve early detection of heart risks in breast cancer patients treated with Trastuzumab. Your data remains securely stored and protected, with strict access controls. If you wish to learn more, withdraw consent, or exercise your data rights, click here to read the full notice.

The study aims to:
(1) Evaluate the predictive capability of chosen cardiac biomarkers in forecasting cardiac dysfunction in breast cancer patients treated with Trastuzumab.
(2) Develop a predictive model using machine learning techniques based on the most accurate and sensitive combination of biomarkers.

Estrogen receptor positive (ER+), human epidermal receptor 2 negative (HER2-) early-stage, resected, invasive breast cancer without evidence of distant metastasis.

To measure how well imlunestrant works compared to standard hormone therapy in patients with early-stage breast cancer that is ER+ and HER2-.